Research Analysts Issue Forecasts for CRBU Q2 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Research analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for shares of Caribou Biosciences in a research report issued on Thursday, May 7th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.36). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.30) per share. Brookline Capital Markets also issued estimates for Caribou Biosciences’ Q3 2026 earnings at ($0.48) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.43) EPS, FY2028 earnings at ($2.05) EPS, FY2029 earnings at ($3.70) EPS and FY2030 earnings at ($5.13) EPS.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. Caribou Biosciences had a negative net margin of 1,189.14% and a negative return on equity of 84.17%. The business had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.21 million.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright raised their price target on shares of Caribou Biosciences from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Monday, April 20th. Finally, Truist Financial raised shares of Caribou Biosciences to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU opened at $2.03 on Tuesday. Caribou Biosciences has a fifty-two week low of $0.77 and a fifty-two week high of $3.54. The stock has a market cap of $201.34 million, a price-to-earnings ratio of -1.43 and a beta of 2.27. The firm’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $1.86.

Hedge Funds Weigh In On Caribou Biosciences

Hedge funds have recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Caribou Biosciences during the 3rd quarter worth approximately $29,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Caribou Biosciences during the 4th quarter worth approximately $25,000. Liberty Wealth Management LLC purchased a new stake in shares of Caribou Biosciences during the 3rd quarter worth approximately $45,000. Westmount Partners LLC purchased a new stake in shares of Caribou Biosciences during the 1st quarter worth approximately $37,000. Finally, Creative Planning purchased a new stake in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.